COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab by Dimai, S. et al.
RESEARCH ARTICLE
COVID19-associated cardiomyocyte
dysfunction, arrhythmias and the effect of
Canakinumab
Sanzio Dimai1,2☯, Lukas Semmler1,3☯, Ashok Prabhu1,3, Harald StachelscheidID
4,
Judith Huettemeister1, Sandra C. Klaucke5, Philipp Lacour1,3, Florian Blaschke1,3,
Jan Kruse6, Abdul Parwani1,3, Leif-Hendrik Boldt1,3, Lars Bullinger7, Burkert
M. Pieske1,3,4,8, Frank R. Heinzel1,3☯, Felix HohendannerID
1,3,4☯*
1 Department of Internal Medicine and Cardiology, Charité University Medicine, Berlin, Germany, 2 Institut
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Cardiac injury associated with cytokine release frequently occurs in SARS-CoV-2 mediated
coronavirus disease (COVID19) and mortality is particularly high in these patients. The
mechanistic role of the COVID19 associated cytokine-storm for the concomitant cardiac
dysfunction and associated arrhythmias is unclear. Moreover, the role of anti-inflammatory
therapy to mitigate cardiac dysfunction remains elusive.
Aims and methods
We investigated the effects of COVID19-associated inflammatory response on cardiac cel-
lular function as well as its cardiac arrhythmogenic potential in rat and induced pluripotent
stem cell derived cardiomyocytes (iPS-CM). In addition, we evaluated the therapeutic poten-
tial of the IL-1β antagonist Canakinumab using state of the art in-vitro confocal and ratio-
metric high-throughput microscopy.
Results
Isolated rat ventricular cardiomyocytes were exposed to control or COVID19 serum from
intensive care unit (ICU) patients with severe ARDS and impaired cardiac function (LVEF
41±5%; 1/3 of patients on veno-venous extracorporeal membrane oxygenation; CK 154±43
U/l). Rat cardiomyocytes showed an early increase of myofilament sensitivity, a decrease of
Ca2+ transient amplitudes and altered baseline [Ca2+] upon exposure to patient serum. In
addition, we used iPS-CM to explore the long-term effect of patient serum on cardiac
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electrical and mechanical function. In iPS-CM, spontaneous Ca2+ release events were more
likely to occur upon incubation with COVID19 serum and nuclear as well as cytosolic Ca2+
release were altered. Co-incubation with Canakinumab had no effect on pro-arrhythmogenic
Ca2+ release or Ca2+ signaling during excitation-contraction coupling, nor significantly influ-
enced cellular automaticity.
Conclusion
Serum derived from COVID19 patients exerts acute cardio-depressant and chronic pro-
arrhythmogenic effects in rat and iPS-derived cardiomyocytes. Canakinumab had no benefi-
cial effect on cellular Ca2+ signaling during excitation-contraction coupling. The presented
method utilizing iPS-CM and in-vitro Ca2+ imaging might serve as a novel tool for precision
medicine. It allows to investigate cytokine related cardiac dysfunction and pharmacological
approaches useful therein.
Introduction
The current Sars-CoV-2 pandemic affects health care systems worldwide in an unprecedented
way, resulting in high morbidity and mortality. Cardiac injury occurs in almost 20% of patients
during hospitalization and mortality is particularly high in these patients [1]. Troponin eleva-
tions are a frequently reported finding [2] and arrythmias are linked to ICU admission in up
to 12% of patients, while acute respiratory distress syndrome (ARDS) and sepsis occur in up to
29% of hospital admissions [3]. In addition, a considerable number of patients present with
cardiovascular comorbidities (up to 15%) worsening their overall outcome. Systemic inflam-
mation and cytokine release are a hallmark feature of the disease [4].
However, the role of COVID19 associated cytokine-storm for concomitant cardiac dys-
function [5] remains elusive. In addition, potential beneficial effects of immunomodulation to
decrease circulatory cytokines with their assumed negative impact on cardiac contractile func-
tion have not yet been established. Cardiac mechanical and electrical function are disturbed
during heart failure with reduced ejection fraction (HFrEF) leading to acute decompensation,
ventricular tachyarrhythmias and sudden cardiac death. HFrEF is a feared complicator of sep-
tic conditions on the ICU and associated with increased mortality [6]. Direct and indirect trig-
gers for HFrEF include infectious viral diseases. It is widely known that a variety of viruses
causes inflammatory cardiomyopathy leading to impaired function [7].
However, besides direct infection of myocytes with cardiotropic viruses, septic cardiomy-
opathy is a common denominator of severely affected ICU patients that suffer from a variety
of viral infections. Septic cardiomyopathy has been associated with an altered interleukin pro-
file in peripheral blood samples [8] and interleukins like TNFα and IL-1β have been shown to
depress myocardial contractile function [9]. Clinical reports indicate that critically ill
COVID19 patients develop sepsis and ARDS at days 10 and 12, which is paralleled by a surge
of cytokines (i.e. IL-1, IL-2, IL-6, IL-7, IL-10, GSCF, IP-10, MCP1, MIP1A, TNFα) known to
be involved in septic cardiomyopathy and clinical deterioration [3]. Several groups have sug-
gested early-on to utilize immunosuppressant therapy for the treatment of COVID19 associ-
ated sepsis. While the IL-6 receptor blocker Tocilizumab administered to COVID19 patients
in cytokine release syndrome has not shown any benefit in terms of survival in a very recent
multicenter randomized controlled trial [10–12], the IL-1 receptor blockers Anakinra and
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Canakinumab conferred a significant survival benefit in patients with septic hyperinflamma-
tion [10, 13, 14].
The specific effects of anti-inflammatory treatment on the concomitant cardiac contractile
and electric function [5] in the context of COVID19 remain elusive. We investigated the effect
of the COVID19 associated cytokine-release on cardiac function in-vitro using a rat model
and induced pluripotent stem-cell derived cardiomyocytes. For that purpose, we established
an in-vitro setup to study potential effects of anti-inflammatory treatment on cardiac dysfunc-
tion as exemplified by the IL-1β inhibitor Canakinumab.
Material and methods
Chemicals and solutions
Chemicals were obtained from Sigma Aldrich (St. Louis, MO, USA) if not noted otherwise.
Fluorescent dyes Fluo-4 and Fura-2 AM were obtained from Thermo Fisher Scientific (Wal-
tham, MA, USA). Normal Tyrode (NT) solution consisted of (in mM): 30 NaCL, 4 KCl, 2
CaCl, 1 MgCl2, 10 Glucose, 10 HEPES and was pH adjusted to 7.4 with NaOH.
Patient serum
The study was conducted at the Charité Campus Virchow Hospital between 04/2020 and 12/
2020 in accordance with the local ethics committee approval (EA2/066/20; pa-COVD19/Char-
ité; “Ethikausschuss am Campus Virchow Klinikum”; Head: PD Dr. E. Kaschina). Patients
provided informed written consent to have data from their medical records used in research
and to participate in this study. Patient serum was acquired from either healthy control donors
(n = 3) or SARS-CoV-2 positive patients (n = 12) with severe acute respiratory distress syn-
drome (i.e. Horowitz index<300; see Table 1 for patient characterization) immediately upon
intensive care unit (ICU) admission. Serum was obtained using a serum separator tube upon
immediate cooled centrifugation and stored at -80˚C. Patient characteristics are shown in
Table 1 and ELISAs were performed for interleukin(IL)-1β, IL-6 and TNFα as per kit instruc-
tions (Invitrogen/Thermo Fisher Scientific, USA). C-reactive protein (CRP), procalcitonin
(PCT), creatinine kinase (CK) and hemoglobin (Hb) concentrations were obtained using the
clinical routine laboratory infrastructure at Charité University Medicine Berlin.
Animal in-vitro experiments
All animal experiments were approved by local authorities and performed in accordance with
local guidelines (local ethical committee approval T0060-15, LAGeSo Berlin). Ventricular car-
diomyocytes were isolated from 12 to 16 weeks old, male Sprague Dawley rats as previously
described [17]. In short, rats were sacrificed using cervical dislocation, hearts were excised,
the aorta was cannulated and mounted on a Langendorff apparatus. Perfusion with a calcium
(Ca2+) free solution for 2 min was followed by enzymatic digestion in a solution containing
20 μM Ca2+ and 75μg/ml Liberase (Sigma-Aldrich (St. Louis, MO, USA) for 12 to 15 min. The
left ventricle was removed from the heart, the tissue was dissected, filtered and washed and
Ca2+ was introduced stepwise. Isolated cardiomyocytes were kept in NT solution between
experiments.
Isolated adult rat ventricular cardiomyocytes were used for two different sets of experi-
ments: First, we investigated effects upon ultra-short term (i.e. 15 min) and second upon
short-term (i.e. 60 min) incubation in either patient or control serum. For the ultra-short term
study, aiming at acute receptor mediated effects, a subset of ventricular cardiomyocytes was
loaded with Fura-2 AM at 1μM for 15 min and plated on laminin-coated coverslips in NT
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solution. The coverslips were mounted on a computer-controlled-microscope (CytoCypher
MultiCell System, CytoCypher BV, Netherlands), cells were electrically stimulated (1 and 3 Hz
field-stimulation; Myopacer, Ionoptix) and fluorescence (excitation at 340 nm and 385 nm,
emission collected at 510±40) and sarcomere shortening were recorded at 37˚C during steady
state. Subsequently, NT solution was replaced by solution containing either patient or control
serum diluted to 10% and cells were incubated for 15 min. Fluorescence signal and contractil-
ity were measured in a paired fashion (cells individual position was stored digitally) while cells
remained in 10% serum solution.
For the short term study and to mimic in-vivo conditions as closely as possible, ventricular
cardiomyocytes were incubated for 60 min in either patient or control serum diluted to 50% at
room temperature. Cells were then removed from the serum solution, washed twice, plated on
laminin-coated coverslips and loaded with Fura-2 AM at 1 μM for 15 min. The additional
wash-step was introduced to mitigate interferences by the serums autofluorescence and het-
erogeneity in local fluorescence.
Fluorescence and contractility were assessed as described above. Recorded fluorescence and
contractility data were analyzed using the software Cytosolver Desktop (CytoCypher MultiCell
System, CytoCypher BV, Netherlands).
Human induced pluripotent stem cells experiments
iPS-derived cardiomyocytes (iPS-CM) were generated from the previously established hiPSC
line BIHi004-A generated from cells of a healthy donor (see Hossini et al. [18] and https://
hpscreg.eu/cell-line/BIHi004-A for further details) using an in-house optimized protocol
established at the BIH Stem Cell Core that is based on the protocol described by Lian et al [19].
IPS-CM were incubated for 24 hours in either patient or control (healthy donors) serum
diluted to 10% with maintenance medium (RPMI 1640 Thermo Fisher Scientific, USA with
B27 Supplement (50X) Thermo Fisher Scientific, USA) at 37.5˚C. Incubation was performed
with or without 10μg/ml of the monoclonal anti-IL-1β antibody Canakinumab (Novus Biolog-
icals, Colorado, USA) present. Cells were subsequently loaded with Fluo-4-AM and
Table 1. Patient characteristics of the study cohort. [15, 16].
COVID19 (n = 12) Control (n = 3) Reference Range
Sex (%) ♂: 75 / ♀: 25 ♂: 100/ ♀: 0 -
Age (ys) 64±4 35±6 -
LVEF (%) 41±5 58±2 55–70
VV-ECMO (%) 33 0 -
CVVHD (%) 58 0 -
Anticoagulation (%) 100 0 -
Glucorticoids (%) 67 - -
Antibiotics (%) 92 - -
Hb (mg/dl) 9.1±0.3 - ♂: >13.5 / ♀: >12
CK (U/l) 154±43 - ♂: <170 / ♀: <145
CRP (mg/dl) 173±30 - <5
PCT (μg/l) 6.6±2.4 - <0.5
Catecholamines (μg/kg/h) 0.06625±0.03 0 -
Horowitz-Ratio 220±24 - >500
IL-6 (pg/ml) 12±7 0.5±0.1 <4.5 (Todd et al; 15)
IL-1β (pg/ml) 2±1 < 0.1 0.3–1.4 (Iorio et al; 16)
TNFα (pg/ml) 23±1 18±8 <2.5 (Todd et al; 15)
https://doi.org/10.1371/journal.pone.0255976.t001
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fluorescence was measured using confocal line-scan imaging (Zeiss LSM 800, excitation at 488
nm, emission collected at> 515 nm). Clusters of cells were identified and the scan line was
placed along the maximal diameter of at least one cell with a pixel-size of 0.12 μm. Cells were
paced at 1 Hz (field-stimulation) and images were acquired either during steady-state or
immediately upon cessation of electrical stimulation as indicated. Local Ca2+ transients were
calculated as F / F0 from regions that were identified to be cytosolic or nuclear using 2D confo-
cal images of cell-clusters. Spontaneous Ca2+ release measurements were obtained during a 10
sec period upon termination of electrical stimulation.
Statistical analysis
Experiments with serum were performed in a non-pooled fashion for each individual patient.
All data is presented as mean ± standard error mean and analysis was performed in a blinded-
fashion. Wherever feasible, individual data points are displayed, otherwise sample sizes are
provided. Parts of the data analysis were conducted in R (version 3.6.1, R Core Team (2018)),
scripts are fully available upon request. GraphPad Prism was used for statistical inference and
plotting (GraphPad Software, San Diego, California USA). To test for group differences, for
data with two groups student’s t-test or Kruskal-Wallis One Way ANOVA on Ranks in non-
normal distributed data was used. For data with more than two groups ANOVA analysis was
performed. A p<0.05 indicates significant statistical difference.
Results
Patients included in the study were mainly male (n = 12; 75% male), at an age of 64 ± 4 years
and showed an impaired left ventricular ejection fraction of 41 ± 5%. In this severely diseased
patient cohort, 33% of patients were treated with veno-venous ECMO therapy and markers for
cardiac injury and inflammation were increased (mean CK 154±43 U/l, mean CRP 173±30
mg/dl; Table 1).
To test the effects of patient serum on cardiac excitation-contraction coupling mimicking
different clinical scenarios of severe COVID19 mediated ARDS, cardiomyocytes were incu-
bated for an ultra-short, short or long term period in either patient or control serum.
First we performed experiments using ratiometric imaging to determine ultra-short term
(15 minutes incubation) and short term (60 minutes incubation) effects on rat ventricular car-
diomyocyte contractile function during excitation-contraction coupling. When exposing iso-
lated adult rat ventricular cardiomyocytes to COVID19 serum the amplitude and kinetics of
sarcomere shortening were not affected at 15 minutes. Interestingly, in these paired measure-
ments, we observed an augmentation of contractile function upon addition of control and
patient serum alike (difference of amplitude after and before incubation: +183% ± 27% vs
+145% ± 16% (control vs patient), n = 75 vs 193, p = 0.23). After 60 minutes at either 1 Hz or 3
Hz maximum sarcomere shortening was still unaffected (1Hz: 0.06. ± 0.003 vs 0.06 ± 0.004
(control vs patient), μm, n = 167 vs 157, p = 0.87; 3 Hz: 0.045 ± 0.003 vs 0.044 ± 0.003 (control
vs patient), μm, n = 126 vs 101, p = 0.78). Although we did see a slight shortening of diastolic
sarcomere length with patient serum at 1 Hz, this was not seen at 3 Hz (1 Hz: 1.59 ± 0.003 vs
1.58 ± 0.003 (control vs patient), μm, n = 169 vs 157, p = 0.03; 3 Hz: 1.59 ± 0.003 vs
1.58 ± 0.004 (control vs patient), μm, n = 126 vs 101, p = 0.36). In addition, contraction and
relaxation kinetics were unaltered (Fig 1).
In a next step, we determined Ca2+ transient amplitudes upon short term exposure to
COVID19 serum.
Incubation with patient serum significantly reduced Ca2+ transient amplitudes at 1 Hz in
comparison to control serum (0.79 ± 0.04 vs 0.68 ± 0.04 (control vs patient), arbitrary units,
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n = 148 vs 157, p = 0.08) with an even more pronounced effect at 3 Hz (1.08 ± 0.07 vs
0.77 ± 0.05. (control vs patient), arbitrary units, n = 117 vs 123, p = 0.01). The positive inotro-
pic cellular response to the increase in stimulation frequency was almost completely blunted
with patient serum (difference of amplitude 3 Hz to 1 Hz: +0.29 vs +0.09 (control vs patient)).
The decrease in amplitude was accompanied by a reduction of diastolic Ca2+ at both frequen-
cies (1Hz: 2.83 ± 0.11 vs 2.26 ± 0.07 (control vs patient), arbitrary units, n = 148 vs 157, p<
0.001; 3 Hz: 2.99 ± 0.1 vs 2.58 ± 0.08 (control vs patient), arbitrary units, n = 117 vs 123,
p = 0.002) (Fig 2).
To further investigate the impact of COVID19 serum on short-term cardiomyocyte func-
tion, we computed Ca2+-contractility loops and calculated the Ca2+ concentration at 50% sar-
comere relaxation, a phase of the loop where the Ca2+-contractility relation is almost linear
(Fig 2). This parameter has previously been described as a measure of microfilament Ca2+
Fig 1. Excitation-contraction coupling in rat cardiomyocytes after 15 (A-D) and 60 (E-I) minutes incubation in either control (black) or
COVID19 (grey) plasma, respectively. (A-D) Depicted as change after incubation in percent of initial value. (A) relative sarcomere shortening
amplitude. (B) diastolic sarcomere length, (C) time to peak of sarcomere shortening and (D) time to 90% of relaxation. (E) Sarcomere
shortening averaged over all cells per group at 1 Hz (upper) and 3 Hz (lower) electric stimulation and 1 mM extracellular [Ca2+]. Related data
of (F) sarcomere shortening amplitude, (G) diastolic sarcomere length, (H) time to sarcomere shortening peak and (I) time to 90% sarcomere
relaxation. �p<0.05.
https://doi.org/10.1371/journal.pone.0255976.g001
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sensitivity [20]. With patient serum, it decreased significantly, indicating an increased Ca2+
sensitivity (1 Hz: 3.15 ± 0.13 vs 2.57 ± 0.07 (control vs patient), arbitrary units, n = 139 vs 142,
p<0.001; 3 Hz: 3.58 ± 0.16 vs 2.97 ± 0.10 (control vs patient), arbitrary units, n = 105 vs 90,
p = 0.01) [21].
To overcome issues with longevity of isolated adult cardiomyocytes and to test our pharma-
cological approach with IL-1β inhibition in a setting that resembles human cardiomyocytes
more closely, we used iPS-CM for our long term experiments. As shown in Fig 3, after 24
hours incubation Ca2+ signaling during excitation-contraction signaling was significantly aug-
mented in the cytosolic compartment, indicating profound changes of the Ca2+ release
machinery. However, addition of Canakinumab had no significant effect on Ca2+ transient
amplitudes (Fig 3).
Fig 2. Ca2+ signaling during excitation-contraction coupling (rat) after 60 minutes incubation with control (black) or COVID19
(grey) serum. (A) Ca2+ transients averaged over all cells per group at 1 Hz (upper) and 3 Hz (lower) electric stimulation and 1 mM
extracellular [Ca2+]. Related data of (B) Ca2+ transient amplitude, (C) diastolic Ca2+, (D) time to Ca2+ transient peak and (E) time to
90% relaxation. (F) Cardiomyocyte Ca2+-sarcomere loop; all-cell/group average at 1 Hz (left) and 3 Hz (right). (G) [Ca2+] at 50%
sarcomere relaxation. �p<0.05, �� p< 0.005, ��� p< 0.001.
https://doi.org/10.1371/journal.pone.0255976.g002
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Long-term incubation with COVID19 patient serum also had effects on cellular arrhythmo-
genic potential: Ca2+ waves showed a trend to occur more often upon incubation with patient
serum as compared to control (0.22 ± 0.04 vs 0.37 ± 0.04 (control vs patient), waves/sec, n = 32
vs 49, p = 0.079) and spontaneous Ca2+ release events (i.e. Ca2+ sparks) were increased upon
addition of COVID serum (Fig 4). Spontaneous action potential activity of iPS-CM is depen-
dent on the proper function of membrane ion channels and cell-cell interactions [22]. We
measured the return of spontaneous action potential generation upon prolonged (i.e. >5 min)
electrical field-stimulation. Cells incubated with control serum had a significantly more fre-
quent return to cellular automaticity after the end of stimulation than those incubated with
patient serum (long term incubation). However, Canakinumab did not affect arrhythmogenic
potential nor the return of cellular automaticity (Fig 4C).
Discussion
The present study used a non-selective approach to study the effect of COVID19 associated
cytokine release on cardiac in-vitro function in ICU patients. Indeed, serum derived from
COVID19 patients was associated with acute cardio-depressant and chronic pro-arrhythmo-
genic effects in both, rat and iPS-CM. This impairment of Ca2+ release might be associated
with the serum protein and cytokine profile of our set of ICU COVID19 patients: It has been
shown that levels of IL-1, TNFα, IL6 and other cytokines are significantly increased in patients
resembling our clinical collective with COVID19 [23–25]. However, of note, 92% of the
patients included in this study received antibiotic treatment at the time of sample acquisition.
This indicates bacterial superinfection and might be a confounding factor in this collective.
67% of the included patients also received glucocorticoids potentially altering the cytokine
profile. IL-1 and TNFα are known pro-inflammatory cytokines with negative effects on cellu-
lar Ca2+ signaling during excitation contraction coupling in septic cardiomyopathy [26]. Even
Fig 3. Ca2+ transients during electrical stimulation of iPS-CM upon addition of COVID19 serum. (A) Example Ca2+ transients as obtained after 24 hours
incubation with serum +/- Canakinumab; iPS-CM during 1Hz electrical field stimulation. (B) Quantification of cytosolic (top) and nuclear (bottom) peak Ca2+
transient amplitudes. �p<0.05.
https://doi.org/10.1371/journal.pone.0255976.g003
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though poorly correlated to survival in COVID19 [27], especially IL-1β has been shown to
decrease the beta-adrenergic responsiveness of L-type Ca2+ channels in a cAMP-independent
mechanism, potentially decreasing cellular inotropic response [28]. This is in line with our
observed altered cytosolic [Ca2+] at 60 minutes serum incubation and further supported by
results from Mitrokhin et al [29], associating electrical abnormalities and action potential pro-
longations with IL-1.
We detected a significant difference in Ca2+ sensitivity upon cellular exposure to COVID19
serum. Notably, among critically ill patients with COVID19, ventricular malign arrhythmias
were found in 2.5% of patients and especially prevalent in non-survivors (RR: 3.8) [30]. As
demonstrated by Huke et al., regional slowing of impulse propagation, which can subsequently
trigger reentrant activation and arrhythmias, is associated with altered Ca2+ sensitivity [31].
Our observed changes in Ca2+ sensitivity might contribute to the arrhythmogenic potential in
severe COVID19 as this relation has been previously described for other models of septic car-
diomyopathy [32].
Arrhythmic Ca2+ release was observed especially after long-term exposure to COVID19
serum. In the present study, the IL-1β blocker Canakinumab was used to potentially mitigate
Fig 4. Arrhythmogenic Ca2+ release in iPS-CM upon addition of COVID19 serum and treatment with Canakinumab. (A) Example for stimulated and spontaneous
(“cellular automaticity”) Ca2+ transients in iPS-CM as obtained after 24 hours incubation with serum +/- Canakinumab; Electrical field-stimulation with 1 Hz as
indicated (black arrows). (B) Spontaneous Ca2+ release events in iPS-CM upon prolonged 1 Hz electrical stimulation. (C) Quantification of cellular automaticity and Ca2+
release events in iPS-CM. �p<0.05.
https://doi.org/10.1371/journal.pone.0255976.g004
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these in-vitro effects, as Canakinumab has been shown to improve outcomes in mild or severe
COVID19 pneumonia in early clinical trials with limited numbers of patients [33]. However,
chronic co-incubation with Canakinumab had no beneficial effect on cellular Ca2+ signaling
during excitation-contraction coupling or on electrical dysfunction in our iPS-CM model.
This missing effect might be linked to our heterogeneous patient collective and sample acquisi-
tion in a real-life scenario–yet it is supported by a very recent randomized clinical trial with
over 450 patients, indicating only little effect of Canakinumab on overall patient outcome
(CAN-COVID; trial identifier: NCT04362813). Further clinical trials like the currently con-
ducted three C study [34] are going to assess potential benefits of Canakinumab treatment
in COVID19 patients limited to cardiac effects. The presented method utilizing iPS-CM and
Ca2+ imaging allows to study acute and chronic cardiac effects in conditions associated with
cytokine release. As exemplified in the current study using Canakinumab, this approach might
also serve as an in-vitro “assay” to assess the effectiveness of different drugs in this particular
setting.
In conclusion, serum derived from COVID19 patients exerts acute cardio-depressant and
chronic pro-arrhythmogenic effects in rat and iPS-derived cardiomyocytes, respectively.
Chronic co-incubation with Canakinumab had no beneficial effect on cellular Ca2+ signaling
during excitation-contraction coupling. The presented method utilizing iPS-CM to screen for
the effectiveness of different pharmacological approaches in the context of conditions associ-
ated with cytokine release might serve as a novel method for precision medicine.
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